[Full remission of acute non-lymphatic leukemia lasting for 16 months following combination therapy with aclacinomycin A].
After pretreatment with anthracyclines, a boy entered a second complete remission of an acute myeloid leukemia lasting already for 16 months following chemotherapy with Aclacinomycin A combined with Etoposide, Cytosine Arabinoside and Thioguanine. The newly developed Aclacinomycin A was well tolerated. Presumably there is no cross resistance between Aclacinomycin A and the anthracyclines, the latter being in use for the therapy of leukemias since some time.
Beck
J D
JD
D015250:Aclarubicin; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D003561:Cytarabine / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D009279:Naphthacenes / Q000008:administration & dosage; D013866:Thioguanine / Q000008:administration & dosage
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D003561:Cytarabine; D005047:Etoposide; D015250:Aclarubicin; D013866:Thioguanine
Seit 16 Monaten anhaltende zweite Vollremission einer akuten nicht lymphatischen Leukämie nach Kombinationstherapie mit Aclacinomycin A.